TriSalus Life Sciences (TLSI) Competitors $4.87 -0.01 (-0.20%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$4.89 +0.02 (+0.41%) As of 09/23/2025 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLSI vs. IRMD, EMBC, TNDM, AXGN, SIBN, BVS, AVNS, ZIMV, KIDS, and TMCIShould you be buying TriSalus Life Sciences stock or one of its competitors? The main competitors of TriSalus Life Sciences include iRadimed (IRMD), Embecta (EMBC), Tandem Diabetes Care (TNDM), AxoGen (AXGN), SiBone (SIBN), Bioventus (BVS), Avanos Medical (AVNS), ZimVie (ZIMV), OrthoPediatrics (KIDS), and Treace Medical Concepts (TMCI). These companies are all part of the "medical equipment" industry. TriSalus Life Sciences vs. Its Competitors iRadimed Embecta Tandem Diabetes Care AxoGen SiBone Bioventus Avanos Medical ZimVie OrthoPediatrics Treace Medical Concepts iRadimed (NASDAQ:IRMD) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends. Which has stronger valuation & earnings, IRMD or TLSI? iRadimed has higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiRadimed$73.24M12.43$19.23M$1.6244.18TriSalus Life Sciences$35.99M6.75-$30.05M-$1.18-4.13 Which has more volatility & risk, IRMD or TLSI? iRadimed has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Does the media favor IRMD or TLSI? In the previous week, iRadimed had 3 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 7 mentions for iRadimed and 4 mentions for TriSalus Life Sciences. iRadimed's average media sentiment score of 1.02 beat TriSalus Life Sciences' score of 0.53 indicating that iRadimed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TriSalus Life Sciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate IRMD or TLSI? iRadimed currently has a consensus target price of $72.00, suggesting a potential upside of 0.60%. TriSalus Life Sciences has a consensus target price of $10.90, suggesting a potential upside of 123.82%. Given TriSalus Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe TriSalus Life Sciences is more favorable than iRadimed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iRadimed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00TriSalus Life Sciences 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Is IRMD or TLSI more profitable? iRadimed has a net margin of 26.61% compared to TriSalus Life Sciences' net margin of -86.61%. iRadimed's return on equity of 23.30% beat TriSalus Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets iRadimed26.61% 23.30% 20.62% TriSalus Life Sciences -86.61%N/A -116.50% Do insiders and institutionals hold more shares of IRMD or TLSI? 92.3% of iRadimed shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 36.8% of iRadimed shares are owned by company insiders. Comparatively, 27.5% of TriSalus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryiRadimed beats TriSalus Life Sciences on 13 of the 17 factors compared between the two stocks. Get TriSalus Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLSI vs. The Competition Export to ExcelMetricTriSalus Life SciencesMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$243.35M$10.70B$5.76B$10.50BDividend YieldN/A1.90%5.53%4.57%P/E Ratio-4.1320.5975.9626.62Price / Sales6.7538.02473.7891.77Price / CashN/A24.5937.4661.85Price / Book-5.873.4013.486.45Net Income-$30.05M$212.47M$3.29B$271.57M7 Day Performance1.46%0.14%1.83%2.61%1 Month Performance-3.56%-2.71%4.00%7.28%1 Year Performance20.25%-10.38%75.89%29.60% TriSalus Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLSITriSalus Life Sciences2.9056 of 5 stars$4.87-0.2%$10.90+123.8%+16.5%$243.35M$35.99M-4.13106News CoverageIRMDiRadimed4.7809 of 5 stars$71.46-0.2%$72.00+0.8%+45.8%$908.97M$73.24M44.11110Positive NewsEMBCEmbecta4.4418 of 5 stars$15.08flat$19.00+26.0%-4.3%$882.03M$1.12B10.552,100Positive NewsTNDMTandem Diabetes Care4.2682 of 5 stars$12.43+2.8%$22.44+80.5%-71.9%$839.90M$940.20M-4.022,650Positive NewsAXGNAxoGen2.8779 of 5 stars$16.73+2.2%$26.00+55.4%+23.8%$769.75M$187.34M-167.28450SIBNSiBone3.7896 of 5 stars$15.10-0.3%$23.67+56.7%-4.0%$651.43M$185.26M-26.96350Positive NewsBVSBioventusN/A$6.84-4.6%N/AN/A$565.53M$573.28M14.461,200AVNSAvanos Medical1.8172 of 5 stars$11.89-3.1%N/A-49.6%$551.72M$692.50M-1.182,227Positive NewsZIMVZimVie1.1762 of 5 stars$18.89flat$17.75-6.0%+18.3%$532.89M$449.75M-26.991,770Positive NewsKIDSOrthoPediatrics4.4129 of 5 stars$19.59+0.2%$34.14+74.3%-30.6%$491.12M$204.73M-10.94200TMCITreace Medical Concepts2.3468 of 5 stars$7.07-2.1%$9.83+39.1%+28.5%$446.61M$209.36M-8.95250 Related Companies and Tools Related Companies iRadimed Competitors Embecta Competitors Tandem Diabetes Care Competitors AxoGen Competitors SiBone Competitors Bioventus Competitors Avanos Medical Competitors ZimVie Competitors OrthoPediatrics Competitors Treace Medical Concepts Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLSI) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Nvidia’s Next Big Invention? (Picture Inside)Nvidia gave investors a chance to make more than 150 times their money with its AI chips known as graphic proc...InvestorPlace | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TriSalus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TriSalus Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
